Global Car T Cell Therapy Treatment Market
Marktgröße in Milliarden USD
CAGR :
% 
 Prognosezeitraum |
2024 –2030 |
 Marktgröße (Basisjahr) | |
 Marktgröße (Prognosejahr) | |
 CAGR |
% |
| Wichtige Marktteilnehmer |
>Globaler Markt für CAR-T-Zelltherapie-Behandlungen, nach Produkt (autologe CAR-T-Zellen, allogene CAR-T-Zellen), Struktur (CAR-T-Zellen der ersten Generation, CAR-T-Zellen der zweiten Generation, CAR-T-Zellen der dritten Generation, CAR-T-Zellen der vierten Generation), gezielte Antigene (Antigene auf soliden Tumoren, Antigene auf hämatologischen Malignomen, sonstige), Marke (Yescarta, Kymriah, Tecartus, sonstige), therapeutische Anwendung (hämatologische Malignome, Bauchspeicheldrüsenkrebs, Brustkrebs, Lungenkrebs, Magenkrebs, Multiples Myelom , chronische lymphatische Leukämie, Mantelzell-Lymphom, follikuläres Lymphom, diffuses großzelliges B-Zell-Lymphom, akute lymphatische Leukämie, sonstige), Endbenutzer (Krankenhäuser, Fachkliniken, sonstige), Vertriebskanal (Krankenhausapotheken, sonstige) – Branchentrends und Prognose bis 2030.
Marktanalyse und -größe für CAR-T-Zelltherapiebehandlungen
CAR-T-Zelltherapie oder chimäre Antigenrezeptor-T-Zellen sind T-Zellen, die gentechnisch so verändert wurden, dass sie einen künstlichen T-Zell-Rezeptor produzieren, der als Immuntherapie zur Behandlung verschiedener Krebsarten eingesetzt werden kann. Chimäre Antigenrezeptoren sind Rezeptorproteine, die im Labor so verändert wurden, dass sie den T-Zellen die neuartige Fähigkeit verleihen, ein bestimmtes Protein gezielt anzugreifen.
Data Bridge Market Research analysiert, dass der Markt für CAR-T-Zelltherapien im Prognosezeitraum von 2023 bis 2030 voraussichtlich eine durchschnittliche jährliche Wachstumsrate von 32,3 % aufweisen wird. „Autologe CAR-T-Zellen“ dominieren das Produktsegment des Marktes für CAR-T-Zelltherapien aufgrund der wachsenden Pharmaindustrie. Neben Einblicken in Marktszenarien wie Marktwert, Wachstumsrate, Segmentierung, geografische Abdeckung und Hauptakteure enthalten die von Data Bridge Market Research zusammengestellten Marktberichte auch eingehende Expertenanalysen, Patientenepidemiologie, Pipeline-Analysen, Preisanalysen und regulatorische Rahmenbedingungen.
Marktumfang und -segmentierung für CAR-T-Zelltherapiebehandlungen
|
Berichtsmetrik |
Details |
|
Prognosezeitraum |
2023 bis 2030 |
|
Basisjahr |
2022 |
|
Historische Jahre |
2021 (anpassbar auf 2015–2021) |
|
Quantitative Einheiten |
Umsatz in Mio. USD, Mengen in Einheiten, Preise in USD |
|
Abgedeckte Segmente |
Produkt (Autologe CAR-T-Zellen, Allogene CAR-T-Zellen), Struktur (CAR-T-Zellen der ersten Generation, CAR-T-Zellen der zweiten Generation, CAR-T-Zellen der dritten Generation, CAR-T-Zellen der vierten Generation), Ziel-Antigene (Antigene auf soliden Tumoren, Antigene auf hämatologischen Malignomen, Sonstiges), Marke (Yescarta, Kymriah, Tecartus, Sonstiges), Therapeutische Anwendung ( Hämatologische Malignome , Bauchspeicheldrüsenkrebs, Brustkrebs, Lungenkrebs, Magenkrebs , Multiples Myelom, Chronische Lymphatische Leukämie, Mantelzell-Lymphom, Follikuläres Lymphom, Diffuses großzelliges B-Zell-Lymphom, Akute Lymphatische Leukämie, Sonstiges), Endverbraucher (Krankenhäuser, Fachkliniken, Sonstiges), Vertriebskanal (Krankenhausapotheke, Sonstiges) |
|
Abgedeckte Länder |
USA, Kanada, Mexiko, Deutschland, Großbritannien, Frankreich, Italien, Spanien, Niederlande, Russland, Schweiz, Belgien, Türkei, Österreich, Norwegen, Ungarn, Litauen, Irland, Polen, Restliches Europa, Japan, China, Australien, Indien, Südkorea, Singapur, Indonesien, Thailand, Malaysia, Philippinen, Vietnam, Restlicher asiatisch-pazifischer Raum, Brasilien, Argentinien, Peru, Restliches Südamerika, Saudi-Arabien, Südafrika, Vereinigte Arabische Emirate, Israel, Kuwait, Ägypten und Restlicher Naher Osten und Afrika. |
|
Abgedeckte Marktteilnehmer |
|
|
Marktchancen |
|
Marktdefinition
Die Behandlung mit chimären Antigenrezeptoren (CAR-T-Zellen) ist eine revolutionäre Immuntherapie zur Behandlung bestimmter Krebsarten. Um einen chimären Antigenrezeptor (CAR) auf der Oberfläche der T-Zellen zu exprimieren, müssen die körpereigenen T-Zellen des Patienten, ein Immunzellsubtyp, genetisch verändert werden. Ziel dieses modifizierten Rezeptors ist es, bestimmte auf Krebszellen vorhandene Antigene anzugreifen.
Marktdynamik für CAR-T-Zelltherapie
Treiber
- Zunehmende Verbreitung zielgerichteter Therapien
CAR-T-Zelltherapien wurden durch die Entwicklung der Präzisionsmedizin und gezielter Therapeutika möglich. Diese Therapien minimieren Schäden an gesundem Gewebe und verringern Nebenwirkungen, indem sie auf bestimmte Antigene auf Krebszellen abzielen.
- Zunehmender technologischer Fortschritt
Werkzeuge zur Genbearbeitung wie CRISPR/Cas9 haben das Design und die Personalisierung von CAR-T-Zellbehandlungen verbessert und so ihre Sicherheit und Wirksamkeit erhöht. Diese laufenden Verbesserungen in den Zelltechniktechniken
- Erhöhung der Finanzierung durch öffentliche und private Behörden
Sowohl öffentliche als auch private Quellen haben beträchtliche Investitionen in das Geschäft mit der CAR-T-Zelltherapie getätigt. Die Entwicklung neuartiger Heilmittel und Technologien wurde durch die finanzielle Unterstützung von Forschung und Entwicklung beschleunigt.
Gelegenheiten
- Wachsende Nachfrage nach personalisierter Medizin
Die Entwicklung personalisierter CAR-T-Zelltherapien, die auf bestimmte Patienten zugeschnitten sind, wird durch Fortschritte in der Genom- und Biomarkerforschung ermöglicht. Diese Strategie kann zu Behandlungen führen, die spezialisierter und effizienter sind und weniger Nebenwirkungen haben.
- Schwellenmarkt mit Expansion
Es gibt keine geografischen Beschränkungen für CAR-T-Zellbehandlungen. Wenn Unternehmen mit gesetzlichen Abweichungen und marktspezifischen Hindernissen umgehen können, bietet die Öffnung des Marktes für weitere Länder und Regionen erhebliche Wachstumsaussichten.
Einschränkungen/Herausforderungen
- Strenge Vorschriften
Lebende Zellen werden bei Zellbehandlungen häufig manipuliert, was besondere regulatorische Schwierigkeiten mit sich bringt. Da die Wirksamkeit und Sicherheit dieser Medikamente von großer Bedeutung ist, müssen strenge regulatorische Verfahren eingehalten werden. Die Überwindung dieser regulatorischen Hürden kann zu einer Verzögerung des Markteintritts und zu höheren Entwicklungskosten führen.
- Hohe Entwicklungskosten
Der Prozess der Entwicklung von Zelltherapien ist zeitaufwändig und teuer. Die Ausgaben für alles von der Forschung und klinischen Tests bis hin zur Herstellung und behördlichen Zulassung können unverhältnismäßig hoch sein. Infolgedessen könnte es weniger Unternehmen geben, die bereit sind, in die Entwicklung von Zelltherapien zu investieren, was die Kosten der Patientenversorgung erhöhen könnte.
- Langfristige Sicherheit und Wirksamkeit
Da die Entwicklung von Zelltherapien relativ neu ist, liegen häufig nur wenige Daten zur langfristigen Sicherheit und Wirksamkeit vor. Um Vertrauen bei medizinischem Fachpersonal, Kostenträgern und Patienten aufzubauen, ist eine regelmäßige Überwachung und Bewertung von Patienten erforderlich, die sich einer Zelltherapie unterziehen.
Dieser Marktbericht zur CAR-T-Zelltherapiebehandlung enthält Einzelheiten zu neuen Entwicklungen, Handelsvorschriften, Import-Export-Analysen, Produktionsanalysen, Wertschöpfungskettenoptimierungen, Marktanteilen, Auswirkungen inländischer und lokaler Marktteilnehmer, analysiert Chancen in Bezug auf neue Einnahmequellen, Änderungen der Marktvorschriften, strategische Marktwachstumsanalysen, Marktgröße, Kategoriemarktwachstum, Anwendungsnischen und -dominanz, Produktzulassungen, Produkteinführungen, geografische Expansionen und technologische Innovationen auf dem Markt. Um weitere Informationen zum Markt für CAR-T-Zelltherapiebehandlungen zu erhalten, wenden Sie sich an Data Bridge Market Research, um einen Analystenbericht zu erhalten. Unser Team hilft Ihnen dabei, eine fundierte Marktentscheidung zu treffen, um Marktwachstum zu erzielen
Globaler Marktumfang für CAR-T-Zelltherapiebehandlungen
Der Markt für CAR-T-Zelltherapien ist segmentiert nach Produkt, Struktur, Zielantigenen, Marke, therapeutischer Anwendung, Endnutzer und Vertriebskanal. Das Wachstum zwischen den Segmenten hilft Ihnen bei der Analyse von Wachstumsnischen und Strategien zur Marktbearbeitung und bestimmt Ihre wichtigsten Anwendungsbereiche und die Unterschiede in Ihren Zielmärkten.
Produkt
- Autologe CAR-T-Zellen
- Allogene CAR-T-Zellen
Struktur
- CAR-T-Zellen der ersten Generation
- CAR-T-Zellen der zweiten Generation
- CAR-T-Zellen der dritten Generation
- CAR-T-Zellen der vierten Generation
Gezielte Antigene
- Antigene auf soliden Tumoren
- Antigene bei hämatologischen Malignomen
- Sonstiges
Marke
- Yescarta
- Kymriah
- Tekartus
- Sonstiges
Therapeutische Anwendung
- Hämatologische Malignome
- Bauchspeicheldrüsenkrebs
- Brustkrebs
- Lungenkrebs
- Magenkrebs
- Multiples Myelom
- Chronische lymphatische Leukämie
- Mantelzell-Lymphom
- Follikuläres Lymphom
- Diffuses großzelliges B-Zell-Lymphom
- Akute lymphatische Leukämie
- Sonstiges
Endbenutzer
- Krankenhäuser
- Spezialkliniken
- Sonstiges
Vertriebskanal
- Krankenhäuser Apotheke
- Sonstiges
Regionale Analyse/Einblicke zum Markt für CAR-T-Zelltherapie-Behandlungen
Der globale Markt für CAR-T-Zelltherapien wird analysiert und Informationen zur Marktgröße werden auf Grundlage von Produkt, Struktur, Zielantigenen, Marke, therapeutischer Anwendung, Endbenutzer und Vertriebskanal wie oben angegeben bereitgestellt.
Die im globalen Marktbericht zur CAR-T-Zelltherapie abgedeckten Länder sind die USA, Kanada, Mexiko, Deutschland, Großbritannien, Frankreich, Italien, Spanien, die Niederlande, Russland, die Schweiz, Belgien, die Türkei, Österreich, Norwegen, Ungarn, Litauen, Irland, Polen, das übrige Europa, Japan, China, Australien, Indien, Südkorea, Singapur, Indonesien, Thailand, Malaysia, die Philippinen, Vietnam, der restliche asiatisch-pazifische Raum, Brasilien, Argentinien, Peru, der restliche Südamerika, Saudi-Arabien, Südafrika, die Vereinigten Arabischen Emirate, Israel, Kuwait, Ägypten sowie der Rest des Nahen Ostens und Afrikas.
Nordamerika dominiert den globalen Markt für CAR-T-Zelltherapien und wird im Prognosezeitraum 2023 bis 2030 voraussichtlich die höchste Wachstumsrate aufweisen, da die Gesundheitsausgaben steigen und die Gesundheitsinfrastruktur für das Segment der autologen CAR-T-Zellen gut ausgebaut ist. Der asiatisch-pazifische Raum ist führend beim Wachstum des globalen Marktes für CAR-T-Zelltherapien und das Segment der autologen CAR-T-Zellen dominiert das Land aufgrund der zunehmenden Forschung zur CAR-T-Zelltherapie.
Der Länderabschnitt des Berichts enthält auch Angaben zu einzelnen marktbeeinflussenden Faktoren und Änderungen der Regulierung auf dem Inlandsmarkt, die sich auf die aktuellen und zukünftigen Markttrends auswirken. Datenpunkte wie Neuverkäufe, Ersatzverkäufe, demografische Daten des Landes, Regulierungsgesetze und Import-/Exportzölle sind einige der wichtigsten Anhaltspunkte, die zur Prognose des Marktszenarios für einzelne Länder verwendet werden. Bei der Prognoseanalyse der Länderdaten werden auch die Präsenz und Verfügbarkeit globaler Marken und ihre Herausforderungen aufgrund großer oder geringer Konkurrenz durch lokale und inländische Marken sowie die Auswirkungen der Vertriebskanäle berücksichtigt.
Wachstum der installierten Basis der Gesundheitsinfrastruktur und Durchdringung mit neuen Technologien
Der Markt für CAR-T-Zelltherapien bietet Ihnen außerdem eine detaillierte Marktanalyse für Patientenanalyse, Prognose und Heilung. Prävalenz, Inzidenz, Mortalität und Adhärenzraten sind einige der im Bericht verfügbaren Datenvariablen. Direkte oder indirekte Auswirkungen der Epidemiologie auf das Marktwachstum werden analysiert, um ein robusteres und kohortenbasiertes multivariates statistisches Modell zur Prognose des Marktes in der Wachstumsphase zu erstellen.
Wettbewerbsumfeld und CAR-T-Zelltherapie-Behandlung Marktanteilsanalyse
Die Wettbewerbslandschaft des Marktes für CAR-T-Zelltherapien liefert Details nach Wettbewerbern. Die enthaltenen Details sind Unternehmensübersicht, Unternehmensfinanzen, erzielter Umsatz, Marktpotenzial, Investitionen in Forschung und Entwicklung, neue Marktinitiativen, Produktionsstandorte und -anlagen, Stärken und Schwächen des Unternehmens, Produkteinführung, Produkttestpipelines, Produktzulassungen, Patente, Produktbreite und -umfang, Anwendungsdominanz, Technologie-Lebenslinienkurve. Die oben angegebenen Datenpunkte beziehen sich nur auf den Fokus des Unternehmens in Bezug auf den globalen Markt für API-Zwischenprodukte.
Zu den wichtigsten Akteuren auf dem Markt für CAR-T-Zelltherapien zählen:
- Autolus (Großbritannien)
- Atara Biotherapeutics, Inc. (USA)
- Amgen Inc. (USA)
- Bellicum Pharmaceuticals, Inc. (USA)
- bluebird bio, Inc. (USA)
- Adaptimmune Therapeutics plc (Großbritannien)
- Bristol-Myers Squibb Company (USA)
- Xyphos (eine Tochtergesellschaft von Astellas Pharma Inc.) (USA)
- Johnson & Johnson Services, Inc. (USA)
- BioAtla Inc. (USA)
- AbbVie Inc. (USA)
- Novartis AG (Schweiz)
- Kite Pharma (eine Tochtergesellschaft von Gilead Sciences, Inc.) (USA)
- Aurora Biopharma (USA)
- Tmunity Therapeutics (USA)
- Cartherics pty. Ltd (Australien)
- CARINA BIOTECH (Australien)
- Ziopharm Oncology, Inc. (USA)
- Cellectis SA (Frankreich)
- Mustang Bio (USA)
- Sorrento Therapeutics, Inc. (USA)
- Cartesian Therapeutics, Inc. (USA)
- TC BioPharm Limited (Großbritannien)
- Celyad Oncology SA (Belgien)
- Tessa Therapeutics Ltd. (Singapur)
SKU-
Erhalten Sie Online-Zugriff auf den Bericht zur weltweit ersten Market Intelligence Cloud
- Interaktives Datenanalyse-Dashboard
- Unternehmensanalyse-Dashboard für Chancen mit hohem Wachstumspotenzial
- Zugriff für Research-Analysten für Anpassungen und Abfragen
- Konkurrenzanalyse mit interaktivem Dashboard
- Aktuelle Nachrichten, Updates und Trendanalyse
- Nutzen Sie die Leistungsfähigkeit der Benchmark-Analyse für eine umfassende Konkurrenzverfolgung
Inhaltsverzeichnis
- introduction
- OBJECTIVES OF THE STUDY
- MARKET DEFINITION
- OVERVIEW of GLOBAL CAR-T cell therapy treatment MARKET
- LIMITATIONs
- MARKETS COVERED
- MARKET SEGMENTATION
- MARKETS COVERED
- geographical scope
- years considered for the study
- currency and pricing
- DBMR TRIPOD DATA VALIDATION MODEL
- MULTIVARIATE MODELLING
- PRODUCT LIFELINE CURVE
- primary interviews with key opinion leaders
- DBMR MARKET POSITION GRID
- vendor share analysis
- MARKET product COVERAGE GRID
- secondary sourcEs
- assumptions
- EXECUTIVE SUMMARY
- premium insight
- Epidemiology
- Pipeline analysis
- Market Overview
- Drivers
- increase in usage of CAR-T CELL THERAPY for the treatment of cancer and infectious diseases
- increasing prevalEnce of cancer
- rise in awareness about immunotherapies
- increasing investment in research and development
- adoption of CAR-T cell therapy treatment in Emerging markets
- restraints
- adverse side effects of therapies
- high cost associated with therapies
- logistic challenge associated with CAR-T therapies
- availability of alternatives for tumor treatment
- opportunities
- presence of pipeline producTs
- strategiC initiatives by market players
- Rise in expenditure in healthcare sector
- challenges
- long approval time for immunotherapies
- lack of skilled professionals
- IMPACT OF COVID-19 ON GLOBAL CAR-T CELL THERAPY TREATMENT MARKET
- IMPACT ON PRICE
- IMPACT ON DEMAND
- IMPACT ON SUPPLY CHAIN
- STRATEGIC DECISION FOR MANUFACTURERS
- CONCLUSION
- global CAR-T Cell Therapy Treatment MARKET, BY PRODUCT
- overview
- Autologous CAR-T Cells
- Allogeneic CAR-T Cells
- global CAR-T CELL THERAPY TREATMENT MARKET, BY Structure
- overview
- First Generation CAR-T Cells
- Second Generation CAR-T Cells
- Third Generation CAR-T Cells
- Fourth Generation CAR-T Cells
- global CAR-T CELL THERAPY TREATMENTMARKET, BY Targeted Antigens
- overview
- Antigens on Hematologic Malignancies
- Cluster of Differentiation-19 (CD-19)
- Cluster of Differentiation-30 (CD-30)
- Cluster of Differentiation-22 (CD-22)
- Cluster of Differentiation-20 (CD-20)
- Cluster of Differentiation-33 (CD-33)
- Antigens on Solid Tumors
- Human Epidermal Growth Factor Receptor-2 (HER-2)
- Epidermal Growth Factor Receptors Variant III (EGFRV-III)
- Mesothelin (MSLN)
- Prostate-Specific Membrane Antigen (PSMA)
- Interleukin-13RA2 (IL13RA2)
- Disialoganglioside 2 (GD2)
- Glypican-3 (GPC3)
- Others
- OTHERS
- global CAR-T cell therapy treatment MARKET, BY brand
- overview
- yescarta
- KYMRIAH
- TECARTUS
- others
- global CAR-T cell therapy treatment MARKET, BY therapeutic application
- overview
- Follicular Lymphoma
- Diffuse Large B-Cell Lymphoma
- Acute Lymphoblastic Leukaemia (ALL)
- Mantle Cell Lymphoma
- Multiple Myeloma
- Hematologic Malignancies
- Leukemia
- Lymphoma
- Myeloma
- Others
- Lung Cancer
- Chronic Lymphocytic Leukemia
- Gastric Cancer
- Pancreatic Cancer
- Breast Cancer
- others
- global CAR-T cell therapy treatment MARKET, BY end user
- overview
- hospitals
- Specialty Clinics
- others
- global CAR-T cell therapy treatment MARKET, BY distribution channel
- overview
- hospital Pharmacy
- others
- Global CAR-T cell therapy treatment market by geography
- Overview
- NORTH AMERICA
- U.S
- Canada
- Mexico
- EUROPE
- germany
- u.k
- France
- Italy
- Spain
- NETHERLANDS
- Russia
- Switzerland
- Belgium
- Turkey
- Austria
- Norway
- Hungary
- Lithuania
- Ireland
- Poland
- Rest of Europe
- ASIA-PACIFIC
- japan
- Australia
- Singapore
- China
- South Korea
- INDIA
- Malaysia
- Thailand
- Indonesia
- Philippines
- Vietnam
- rest of asia-pacific
- SOUTH AMERICA
- BRAZIL
- aRGENTINA
- PERU
- REST OF SOUTH AMEERICA
- MIDDLE EAST AND AFRICA
- sAUDI ARABIA
- UAE
- SOUTH AFRICA
- ISRAEL
- KUWAIT
- egypt
- rest of middle east and africa
- Global CAR-T Cell Therapy Treatment Market: COMPANY landscape
- company share analysis: global
- company share analysis: north america
- company share analysis: europe
- company share analysis: Asia-Pacific
- swot analysis
- company profile
- kite pharma (A subsidiary of GILEAD SCIENCES, INC.)
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- company share analysis
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- Novartis AG
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- company share analysis
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- Abbvie inc.
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- Adaptimmune Therapeutics plc
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- Amgen Inc.
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PIPELINE PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- Atara Biotherapeutics, Inc.
- COMPANY SNAPSHOT
- PIPELINE PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- aurora biopharmA
- COMPANY SNAPSHOT
- PIPELINE PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- Autolus
- COMPANY SNAPSHOT
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- Bellicum Phamaceuticals, Inc.
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- BioAtla Inc.
- COMPANY SNAPSHOT
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- bluebird bio, inc.
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- Bristol-Myers Squibb Company
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- carina biotech
- COMPANY SNAPSHOT
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- cartherics pty ltd
- COMPANY SNAPSHOT
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- cartesian therapeutics, inc.
- COMPANY SNAPSHOT
- PIPELINE PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- cellectis SA
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- celyad oncology SA
- COMPANY SNAPSHOT
- PIPELINE PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- Johnson & Johnson Services, Inc.
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- sorrento therapeutics, INC.
- COMPANY SNAPSHOT
- PIPELINE PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- tc biopharm Limited
- COMPANY SNAPSHOT
- PIPELINE PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- tessa therapeutics ltd.
- COMPANY SNAPSHOT
- PIPELINE PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- tmunity therapeutics
- COMPANY SNAPSHOT
- PIPELINE PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- mustang bio
- COMPANY SNAPSHOT
- PIPELINE PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- Xyphos (A Subsidiary of Astellas Pharma Inc.)
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PIPELINE PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- ziopharm oncology, inc.
- COMPANY SNAPSHOT
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- questionnaire
- related reports
Tabellenverzeichnis
TABLE 1 Global CAR-T cell therapy treatment Market, pipeline analysis
TABLE 2 Below provided are the alternative chemotherapies of CAR-T cell therapy:
TABLE 3 TOTAL HEALTH SPENDING BY THE U.S. (2015-2016)
TABLE 4 globaL CAR-T CELL THERAPY TREATMENTMarket, By MOLECULE, 2019-2028 (USD Million)
TABLE 5 globaL Autologous CAR-T Cells in CAR-T CELL THERAPY TREATMENTMarket, By Region, 2017-2028 (USD Million)
TABLE 6 globaL Allogeneic CAR-T Cells in CAR-T CELL THERAPY TREATMENTMARKET, By Region, 2019-2028 (USD Million)
TABLE 7 globaL CAR-T CELL THERAPY TREATMENTMarket, By Structure, 2019-2028 (USD Million)
Celyad is engaged in the manufacturing of CYAD-211, a first generation CAR-T cell therapy expressing BCMA targeting chimeric antigen receptor which interferes with the expression of the CD3ζ of T cell receptor complex. 99
TABLE 8 globaL First Generation CAR-T Cells in CAR-T CELL THERAPY TREATMENT Market, By Region, 2019-2028 (USD Million)
TABLE 9 globaL Second Generation CAR-T Cells in CAR-T CELL THERAPY TREATMENT Market, By Region, 2019-2028 (USD Million)
TABLE 10 globaL Third Generation CAR-T Cells in CAR-T CELL THERAPY TREATMENT Market, By Region, 2019-2028 (USD Million)
TABLE 11 globaL Third Generation CAR-T Cells in CAR-T CELL THERAPY TREATMENT Market, By Region, 2019-2028 (USD Million)
TABLE 12 globaL CAR-T CELL THERAPY TREATMENTMarket, By targeted antigens, 2019-2028 (USD Million)
TABLE 13 globaL Antigens on Hematologic Malignancies in CAR-T CELL THERAPY TREATMENT Market, By Region, 2019-2028 (USD Million)
TABLE 14 globaL Antigens on Hematologic Malignancies in CAR-T CELL THERAPY TREATMENT Market, By Antigens on Hematologic Malignancies, 2019-2028 (USD Million)
TABLE 15 globaL Antigens on Solid Tumors in CAR-T CELL THERAPY TREATMENTMarket , By Region, 2017-2028 (USD Million)
TABLE 16 globaL Antigens on Solid Tumors in CAR-T CELL THERAPY TREATMENT Market, By Antigens on Solid Tumors, 2019-2028 (USD Million)
TABLE 17 globaL others in CAR-T CELL THERAPY TREATMENTMarket , By Region, 2017-2028 (USD Million)
TABLE 18 globaL YESCARTA in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 19 globaL YESCARTA in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 20 globaL KYMRIAH in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 21 globaL TECARTUS in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 22 globaL others in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 23 globaL CAR-T cell therapy treatment Market, By therapeutic type, 2019-2028 (USD Million)
TABLE 24 globaL Follicular Lymphoma in CAR-T cell therapy treatment Market, By therapeutic type, 2017-2028 (USD Million)
TABLE 25 globaL Diffuse Large B-Cell Lymphoma in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 26 globaL ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL) in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 27 globaL Mantle Cell Lymphoma in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 28 globaL Multiple Myeloma in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 29 globaL hematologic malignancies in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 30 globaL hematologic malignancies on Solid Tumors in CAR-T CELL THERAPY TREATMENT Market, By therapeutic application, 2019-2028 (USD Million)
TABLE 31 globaL Lung Cancer in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 32 globaL chronic lymphocytic leukemia in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 33 globaL gastric cancer in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 34 globaL pancreatic cancer in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 35 globaL breast cancer in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 36 globaL others in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 37 globaL CAR-T cell therapy treatment Market, By END USER, 2019-2028 (USD Million)
TABLE 38 globaL hospitals in CAR-T cell therapy treatment Market, By therapeutic type, 2017-2028 (USD Million)
TABLE 39 globaL specialty clinics in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 40 globaL others in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 41 globaL CAR-T cell therapy treatment Market, By distribution channel, 2019-2028 (USD Million)
TABLE 42 globaL hospital pharmacy in CAR-T cell therapy treatment Market, By distribution channel, 2017-2028 (USD Million)
TABLE 43 globaL others in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 44 GLOBAL CAR-T cell therapy treatment MARKET, BY REGION , 2021-2028 (USD MILLION)
TABLE 45 North America CAR-T Cell Therapy Treatment Market, By Region, 2019-2028 (USD Million)
TABLE 46 North America CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 47 North America CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 48 North America CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 49 North America Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 50 North America Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 51 North America CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 52 North America CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 53 North America Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 54 North America CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 55 North America CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 56 U.S CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 57 U.S CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 58 U.S CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 59 U.S Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 60 U.S Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 61 U.S CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 62 U.S CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 63 U.S Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 64 U.S CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 65 U.S CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 66 CANADA CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 67 CANADA CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 68 CANADA CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 69 CANADA Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 70 CANADA Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 71 CANADA CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 72 CANADA CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 73 CANADA Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 74 CANADA CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 75 CANADA CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 76 MEXICO CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 77 MEXICO CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 78 MEXICO CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 79 MEXICO Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 80 MEXICO Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 81 MEXICO CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 82 MEXICO CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 83 MEXICO Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 84 MEXICO CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 85 MEXICO CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 86 Europe CAR-T Cell Therapy Treatment Market, By Region, 2019-2028 (USD Million)
TABLE 87 Europe CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 88 Europe CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 89 Europe CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 90 europe Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 91 Europe Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 92 Europe CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 93 Europe CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 94 Europe Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 95 Europe CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 96 Europe CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 97 Germany CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 98 Germany CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 99 Germany CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 100 Germany Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 101 Germany Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 102 Germany CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 103 Germany CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 104 Germany Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 105 Germany CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 106 Germany CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 107 U.K CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 108 U.K CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 109 U.K CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 110 U.K Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 111 U.K Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 112 U.K CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 113 U.K CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 114 U.K Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 115 U.K CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 116 U.K CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 117 FRANCE CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 118 FRANCE CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 119 FRANCE CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 120 FRANCE Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 121 FRANCE Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 122 FRANCE CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 123 FRANCE CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 124 FRANCE Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 125 FRANCE CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 126 FRANCE CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 127 ITALY CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 128 ITALY CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 129 ITALY CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 130 ITALY Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 131 ITALY Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 132 ITALY CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 133 ITALY CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 134 ITALY Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 135 ITALY CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 136 ITALY CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 137 Spain CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 138 SPAIN CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 139 SPAIN CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 140 SPAIN Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 141 SPAIN Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 142 SPAIN CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 143 SPAIN CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 144 SPAIN Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 145 SPAIN CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 146 SPAIN CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 147 netherlands CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 148 NETHERLANDS CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 149 NETHERLANDS CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 150 NETHERLANDS Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 151 NETHERLANDS Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 152 NETHERLANDS CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 153 NETHERLANDS CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 154 NETHERLANDS Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 155 NETHERLANDS CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 156 NETHERLANDS CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 157 Russia CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 158 RUSSIA CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 159 RUSSIA CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 160 RUSSIA Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 161 RUSSIA Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 162 RUSSIA CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 163 RUSSIA CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 164 RUSSIA Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 165 RUSSIA CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 166 RUSSIA CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 167 Switzerland CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 168 SWITZERLAND CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 169 SWITZERLAND CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 170 SWITZERLAND Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 171 SWITZERLAND Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 172 SWITZERLAND CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 173 SWITZERLAND CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 174 SWITZERLAND Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 175 SWITZERLAND CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 176 SWITZERLAND CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 177 belgium CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 178 BELGIUM CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 179 BELGIUM CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 180 BELGIUM Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 181 BELGIUM Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 182 BELGIUM CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 183 BELGIUM CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 184 BELGIUM Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 185 BELGIUM CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 186 BELGIUM CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 187 turkey CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 188 TURKEY CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 189 TURKEY CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 190 TURKEY Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 191 TURKEY Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 192 TURKEY CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 193 TURKEY CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 194 TURKEY Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 195 TURKEY CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 196 turkey CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 197 Austria CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 198 AUSTRIA CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 199 AUSTRIA CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 200 AUSTRIA Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 201 AUSTRIA Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 202 AUSTRIA CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 203 AUSTRIA CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 204 AUSTRIA Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 205 AUSTRIA CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 206 Austria CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 207 norway CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 208 NORWAY CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 209 NORWAY CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 210 NORWAY Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 211 NORWAY Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 212 NORWAY CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 213 NORWAY CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 214 NORWAY Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 215 NORWAY CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 216 Norway CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 217 Hungary CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 218 HUNGARY CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 219 HUNGARY CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 220 HUNGARY Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 221 HUNGARY Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 222 HUNGARY CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 223 HUNGARY CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 224 HUNGARY Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 225 HUNGARY CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 226 Hungary CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 227 Lithuania CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 228 LITHUANIA CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 229 LITHUANIA CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 230 LITHUANIA Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 231 LITHUANIA Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 232 LITHUANIA CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 233 LITHUANIA CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 234 LITHUANIA Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 235 LITHUANIA CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 236 Lithuania CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 237 Ireland CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 238 IRELAND CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 239 IRELAND CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 240 IRELAND Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 241 IRELAND Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 242 IRELAND CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 243 IRELAND CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 244 IRELAND Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 245 IRELAND CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 246 ireland CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 247 Poland CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 248 POLAND CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 249 POLAND CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 250 POLAND Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 251 POLAND Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 252 POLAND CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 253 POLAND CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 254 POLAND Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 255 POLAND CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 256 Poland CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 257 Rest of Europe CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 258 Asia-Pacific CAR-T Cell Therapy Treatment Market, By Region, 2019-2028 (USD Million)
TABLE 259 Asia-Pacific CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 260 Asia-Pacific CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 261 Asia-Pacific CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 262 Asia-Pacific Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 263 Asia-Pacific Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 264 Asia-Pacific CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 265 Asia-Pacific CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 266 Asia-Pacific Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 267 Asia-Pacific CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 268 Asia-Pacific CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 269 Japan CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 270 Japan CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 271 Japan CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 272 Japan Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 273 Japan Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 274 Japan CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 275 Japan CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 276 Japan Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 277 Japan CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 278 Japan CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 279 AUSTRALIA CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 280 AUSTRALIA CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 281 AUSTRALIA CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 282 AUSTRALIA Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 283 AUSTRALIA Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 284 AUSTRALIA CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 285 AUSTRALIA CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 286 AUSTRALIA Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 287 AUSTRALIA CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 288 AUSTRALIA CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 289 SINGAPORE CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 290 SINGAPORE CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 291 SINGAPORE CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 292 SINGAPORE Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 293 SINGAPORE Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 294 SINGAPORE CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 295 SINGAPORE CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 296 SINGAPORE Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 297 SINGAPORE CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 298 SINGAPORE CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 299 CHINA CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 300 CHINA CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 301 CHINA CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 302 CHINA Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 303 CHINA Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 304 CHINA CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 305 CHINA CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 306 CHINA Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 307 CHINA CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 308 CHINA CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 309 South Korea CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 310 SOUTH KOREA CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 311 SOUTH KOREA CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 312 SOUTH KOREA Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 313 SOUTH KOREA Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 314 SOUTH KOREA CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 315 SOUTH KOREA CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 316 SOUTH KOREA Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 317 SOUTH KOREA CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 318 SOUTH KOREA CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 319 India CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 320 INDIA CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 321 INDIA CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 322 INDIA Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 323 INDIA Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 324 INDIA CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 325 INDIA CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 326 INDIA Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 327 INDIA CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 328 INDIA CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 329 Malaysia CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 330 MALAYSIA CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 331 MALAYSIA CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 332 MALAYSIA Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 333 MALAYSIA Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 334 MALAYSIA CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 335 MALAYSIA CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 336 MALAYSIA Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 337 MALAYSIA CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 338 MALAYSIA CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 339 Thailand CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 340 THAILAND CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 341 THAILAND CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 342 THAILAND Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 343 THAILAND Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 344 THAILAND CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 345 THAILAND CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 346 THAILAND Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 347 THAILAND CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 348 THAILAND CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 349 Indonesia CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 350 iNDONESIA CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 351 INDONESIA CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 352 INDONESIA Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 353 INDONESIA Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 354 INDONESIA CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 355 INDONESIA CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 356 INDONESIA Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 357 INDONESIA CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 358 INDONESIA CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 359 Philippines CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 360 PHILIPPINES CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 361 PHILIPPINES CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 362 PHILIPPINES Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 363 PHILIPPINES Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 364 PHILIPPINES CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 365 PHILIPPINES CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 366 PHILIPPINES Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 367 PHILIPPINES CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 368 Philippines CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 369 Vietnam CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 370 VIETNAM CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 371 VIETNAM CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 372 VIETNAM Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 373 VIETNAM Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 374 VIETNAM CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 375 VIETNAM CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 376 VIETNAM Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 377 VIETNAM CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 378 Vietnam CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 379 Rest of Asia-Pacific CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 380 South AMERICA CAR-T Cell Therapy Treatment Market, By Region, 2019-2028 (USD Million)
TABLE 381 SOUTH AMERICA CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 382 SOUTH AMERICA CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 383 SOUTH AMERICA CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 384 SOUTH AMERICA Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 385 SOUTH AMERICA Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 386 SOUTH AMERICA CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 387 SOUTH AMERICA CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 388 SOUTH AMERICA Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 389 SOUTH AMERICA CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 390 SOUTH AMERICA CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 391 BRAZIL CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 392 BRAZIL CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 393 BRAZIL CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 394 BRAZIL Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 395 BRAZIL Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 396 BRAZIL CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 397 BRAZIL CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 398 BRAZIL Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 399 BRAZIL CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 400 BRAZIL CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 401 ARGENTINA CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 402 ARGENTINA CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 403 ARGENTINA CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 404 ARGENTINA Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 405 ARGENTINA Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 406 ARGENTINA CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 407 ARGENTINA CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 408 ARGENTINA Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 409 ARGENTINA CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 410 ARGENTINA CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 411 PERU CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 412 peru CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 413 peru CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 414 peru Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 415 peru Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 416 peru CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 417 peru CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 418 peru Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 419 peru CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 420 peru CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 421 REST OF SOUTH AMERICA CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 422 Middle East and Africa CAR-T Cell Therapy Treatment Market, By Region, 2019-2028 (USD Million)
TABLE 423 Middle East and Africa CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 424 Middle East and Africa CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 425 Middle East and Africa CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 426 Middle East and Africa Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 427 Middle East and Africa Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 428 Middle East and Africa CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 429 Middle East and Africa CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 430 Middle East and Africa Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 431 Middle East and Africa CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 432 Middle East and Africa CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 433 Saudi Arabia CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 434 Saudi Arabia CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 435 Saudi Arabia CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 436 Saudi Arabia Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 437 Saudi Arabia Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 438 Saudi Arabia CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 439 Saudi Arabia CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 440 Saudi Arabia Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 441 Saudi Arabia CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 442 Saudi Arabia CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 443 UAE CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 444 UAE CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 445 UAE CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 446 UAE Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 447 UAE Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 448 UAE CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 449 UAE CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 450 UAE Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 451 UAE CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 452 UAE CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 453 SOUTH AFRICA CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 454 SOUTH AFRICA CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 455 SOUTH AFRICA CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 456 SOUTH AFRICA Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 457 SOUTH AFRICA Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 458 SOUTH AFRICA CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 459 SOUTH AFRICA CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 460 SOUTH AFRICA Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 461 SOUTH AFRICA CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 462 SOUTH AFRICA CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 463 ISRAEL CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 464 ISRAEL CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 465 ISRAEL CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 466 ISRAEL Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 467 ISRAEL Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 468 ISRAEL CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 469 ISRAEL CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 470 ISRAEL Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 471 ISRAEL CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 472 ISRAEL CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 473 KUWAIT CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 474 KUWAIT CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 475 KUWAIT CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 476 KUWAIT Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 477 KUWAIT Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 478 KUWAIT CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 479 KUWAIT CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 480 KUWAIT Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 481 KUWAIT CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 482 KUWAIT CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 483 EGYPT CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 484 EGYPT CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 485 EGYPT CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 486 EGYPT Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 487 EGYPT Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 488 EGYPT CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 489 EGYPT CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 490 EGYPT Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 491 EGYPT CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 492 EGYPT CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 493 EGYPT CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
Abbildungsverzeichnis
FIGURE 1 Global CAR-T cell therapy treatment MARKET: SEGMENTATION
FIGURE 2 GLOBAL CAR-T cell therapy treatment MARKET: DATA TRIANGULATION
FIGURE 3 global CAR-T cell therapy treatment Market: DROC ANALYSIS
FIGURE 4 Global CAR-T cell therapy treatment market: Global VS REGIONAL MARKET ANALYSIS
FIGURE 5 Global CAR-T cell therapy treatment Market: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL CAR-T cell therapy treatment MARKET: MULTIVARIATE MODELLING
FIGURE 7 GLOBAL CAR-T cell therapy treatment MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 GLOBAL CAR-T cell therapy treatment MARKET: DBMR MARKET POSITION GRID
FIGURE 9 GLOBAL CAR-T cell therapy treatment MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 GLOBAL car-t cell therapy treatment MARKET: MARKET product COVERAGE GRID
FIGURE 11 Global car-t cell therapy treatment market: SEGMENTATION
FIGURE 12 NORTH AMERICA is expected to DOMINATE THE GLOBAL CAR-T cell therapy treatment market AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 13 increasing investment in research and development is expected to drive THE global CAR-T cell therapy treatment market IN THE FORECAST PERIOD OF 2021 to 2028
FIGURE 14 Autologus car-t cells SEGMENT is expected to account for the largest share of the global CAR-T CELL THERAPY TREATMENT market in 2021 & 2028
FIGURE 15 ASIA-PACIFIC is the fastest growing market FOR the CAR-T cell therapy treatment MANUFACTURERS IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGEs OF Global CAR-T cell therapy treatment Market
FIGURE 17 New Cancer Cases Worldwide, (2018)
FIGURE 18 Global Cancer Incidence (2018)
FIGURE 19 Cancer Death By Type (in million), world, 2017
FIGURE 20 global CAR-T CELL THERAPY TREATMENTmarket: BY Product, 2021
FIGURE 21 global CAR-T CELL THERAPY TREATMENTmarket: BY Product, 2019-2028 (USD Million)
FIGURE 22 global CAR-T CELL THERAPY TREATMENTmarket: BY Product, CAGR (2021-2028)
FIGURE 23 global CAR-T CELL THERAPY TREATMENTmarket: BY Product, LIFELINE CURVE
FIGURE 24 global CAR-T CELL THERAPY TREATMENTmarket: BY structure, 2021
FIGURE 25 global CAR-T CELL THERAPY TREATMENTmarket: BY structure, 2019-2028 (USD Million)
FIGURE 26 global CAR-T CELL THERAPY TREATMENTmarket: BY structure, CAGR (2021-2028)
FIGURE 27 global CAR-T CELL THERAPY TREATMENTmarket: BY structure, LIFELINE CURVE
FIGURE 28 global CAR-T CELL THERAPY TREATMENTmarket: BY targeted antigens, 2021
FIGURE 29 global CAR-T CELL THERAPY TREATMENTmarket: BY targeted antigens, 2019-2028 (USD Million)
FIGURE 30 global CAR-T CELL THERAPY TREATMENTmarket: BY targeted antigens, CAGR (2021-2028)
FIGURE 31 global CAR-T CELL THERAPY TREATMENTmarket: BY targeted antigens, LIFELINE CURVE
FIGURE 32 global CAR-T cell therapy treatment market: BY brand, 2020
FIGURE 33 global CAR-T cell therapy treatment market: BY brand, 2020-2028 (USD Million)
FIGURE 34 global CAR-T cell therapy treatment market: BY brand, CAGR (2020-2028)
FIGURE 35 global CAR-T cell therapy treatment market: BY brand, LIFELINE CURVE
FIGURE 36 global CAR-T cell therapy treatment market: BY therapeutic application, 2020
FIGURE 37 global CAR-T cell therapy treatment market: BY therapeutic application, 2020-2028 (USD Million)
FIGURE 38 global CAR-T cell therapy treatment market: BY therapeutic application, CAGR (2020-2028)
FIGURE 39 global CAR-T cell therapy treatment market: BY therapeutic application, LIFELINE CURVE
FIGURE 40 global CAR-T cell therapy treatment market: BY END USER, 2020
FIGURE 41 global CAR-T cell therapy treatment market: BY END USER, 2020-2028 (USD Million)
FIGURE 42 global CAR-T cell therapy treatment market: BY END USER, CAGR (2020-2028)
FIGURE 43 global CAR-T cell therapy treatment market: BY END USER, LIFELINE CURVE
FIGURE 44 global CAR-T cell therapy treatment market: BY distribution channel, 2020
FIGURE 45 global CAR-T cell therapy treatment market: BY distribution channel, 2020-2028 (USD Million)
FIGURE 46 global CAR-T cell therapy treatment market: BY distribution channel, CAGR (2020-2028)
FIGURE 47 global CAR-T cell therapy treatment market: BY distribution channel, LIFELINE CURVE
FIGURE 48 GLOBAL CAR-T cell therapy treatment market: SNAPSHOT (2020)
FIGURE 49 GLOBAL CAR-T cell therapy treatment market: BY COUNTRY (2020)
FIGURE 50 GLOBAL CAR-T cell therapy treatment market: BY COUNTRY (2021 & 2028)
FIGURE 51 GLOBAL CAR-T cell therapy treatment market: BY COUNTRY (2020 & 2028)
FIGURE 52 GLOBAL CAR-T cell therapy treatment market: BY PRODUCT (2021-2028)
FIGURE 53 North America CAR-T CELL THERAPY TREATMENT market: SNAPSHOT (2020)
FIGURE 54 North America CAR-T CELL THERAPY TREATMENT market: BY COUNTRY (2020)
FIGURE 55 North America CAR-T CELL THERAPY TREATMENT market: BY COUNTRY (2021 & 2028)
FIGURE 56 North America CAR-T CELL THERAPY TREATMENT market: BY COUNTRY (2020 & 2028)
FIGURE 57 North America CAR-T CELL THERAPY TREATMENT market: BY product (2021-2028)
FIGURE 58 Europe CAR-T CELL THERAPY TREATMENT market: SNAPSHOT (2020)
FIGURE 59 Europe CAR-T CELL THERAPY TREATMENT market: BY COUNTRY (2020)
FIGURE 60 Europe CAR-T CELL THERAPY TREATMENT market: BY COUNTRY (2021 & 2028)
FIGURE 61 Europe CAR-T CELL THERAPY TREATMENT market: BY COUNTRY (2020 & 2028)
FIGURE 62 Europe CAR-T CELL THERAPY TREATMENT market: BY product (2021-2028)
FIGURE 63 Asia-Pacific CAR-T CELL THERAPY TREATMENT market: SNAPSHOT (2020)
FIGURE 64 Asia-Pacific CAR-T CELL THERAPY TREATMENT market: BY COUNTRY (2020)
FIGURE 65 Asia-Pacific CAR-T CELL THERAPY TREATMENT market: BY COUNTRY (2021 & 2028)
FIGURE 66 Asia-Pacific CAR-T CELL THERAPY TREATMENT market: BY COUNTRY (2020 & 2028)
FIGURE 67 Asia-Pacific CAR-T CELL THERAPY TREATMENT market: BY product (2021-2028)
FIGURE 68 South America CAR-T CELL THERAPY TREATMENT market: SNAPSHOT (2020)
FIGURE 69 South America CAR-T CELL THERAPY TREATMENT market: BY COUNTRY (2020)
FIGURE 70 South America CAR-T CELL THERAPY TREATMENT market: BY COUNTRY (2021 & 2028)
FIGURE 71 South America CAR-T CELL THERAPY TREATMENT market: BY COUNTRY (2020 & 2028)
FIGURE 72 South America CAR-T CELL THERAPY TREATMENT market: BY product (2021-2028)
FIGURE 73 Middle East and Africa CAR-T CELL THERAPY TREATMENT market: SNAPSHOT (2020)
FIGURE 74 Middle East and Africa CAR-T CELL THERAPY TREATMENT market: BY COUNTRY (2020)
FIGURE 75 Middle East and Africa CAR-T CELL THERAPY TREATMENT market: BY COUNTRY (2021 & 2028)
FIGURE 76 Middle East and Africa CAR-T CELL THERAPY TREATMENT market: BY COUNTRY (2020 & 2028)
FIGURE 77 Middle East and Africa CAR-T CELL THERAPY TREATMENT market: BY product (2021-2028)
FIGURE 78 Global CAR-T Cell Therapy Treatment market: company share 2020 (%)
FIGURE 79 North America CAR-T Cell Therapy Treatment Market: company share 2020 (%)
FIGURE 80 EUROPE CAR-T Cell Therapy Treatment Market: company share 2020 (%)
FIGURE 81 ASIA-PACIFIC CAR-T Cell Therapy Treatment Market: company share 2020 (%)
Forschungsmethodik
Die Datenerfassung und Basisjahresanalyse werden mithilfe von Datenerfassungsmodulen mit großen Stichprobengrößen durchgeführt. Die Phase umfasst das Erhalten von Marktinformationen oder verwandten Daten aus verschiedenen Quellen und Strategien. Sie umfasst die Prüfung und Planung aller aus der Vergangenheit im Voraus erfassten Daten. Sie umfasst auch die Prüfung von Informationsinkonsistenzen, die in verschiedenen Informationsquellen auftreten. Die Marktdaten werden mithilfe von marktstatistischen und kohärenten Modellen analysiert und geschätzt. Darüber hinaus sind Marktanteilsanalyse und Schlüsseltrendanalyse die wichtigsten Erfolgsfaktoren im Marktbericht. Um mehr zu erfahren, fordern Sie bitte einen Analystenanruf an oder geben Sie Ihre Anfrage ein.
Die wichtigste Forschungsmethodik, die vom DBMR-Forschungsteam verwendet wird, ist die Datentriangulation, die Data Mining, die Analyse der Auswirkungen von Datenvariablen auf den Markt und die primäre (Branchenexperten-)Validierung umfasst. Zu den Datenmodellen gehören ein Lieferantenpositionierungsraster, eine Marktzeitlinienanalyse, ein Marktüberblick und -leitfaden, ein Firmenpositionierungsraster, eine Patentanalyse, eine Preisanalyse, eine Firmenmarktanteilsanalyse, Messstandards, eine globale versus eine regionale und Lieferantenanteilsanalyse. Um mehr über die Forschungsmethodik zu erfahren, senden Sie eine Anfrage an unsere Branchenexperten.
Anpassung möglich
Data Bridge Market Research ist ein führendes Unternehmen in der fortgeschrittenen formativen Forschung. Wir sind stolz darauf, unseren bestehenden und neuen Kunden Daten und Analysen zu bieten, die zu ihren Zielen passen. Der Bericht kann angepasst werden, um Preistrendanalysen von Zielmarken, Marktverständnis für zusätzliche Länder (fordern Sie die Länderliste an), Daten zu klinischen Studienergebnissen, Literaturübersicht, Analysen des Marktes für aufgearbeitete Produkte und Produktbasis einzuschließen. Marktanalysen von Zielkonkurrenten können von technologiebasierten Analysen bis hin zu Marktportfoliostrategien analysiert werden. Wir können so viele Wettbewerber hinzufügen, wie Sie Daten in dem von Ihnen gewünschten Format und Datenstil benötigen. Unser Analystenteam kann Ihnen auch Daten in groben Excel-Rohdateien und Pivot-Tabellen (Fact Book) bereitstellen oder Sie bei der Erstellung von Präsentationen aus den im Bericht verfügbaren Datensätzen unterstützen.
